One of the most extensively studied SARMs. Developed by Ligand Pharmaceuticals and later Viking Therapeutics. Has completed Phase I and entered Phase II trials. Suppresses natural testosterone production.
LGD-4033 is the SARM most commonly used for lean mass building in performance settings. Phase I clinical data showing dose-dependent lean mass increases gave it credibility that most other SARMs lack, which is why it is frequently cited as the most studied and most reliably effective SARM for muscle gain. Athletes and bodybuilders use it in bulking...
LGD-4033 is sometimes combined with MK-677 in a stack that targets both androgen receptor-mediated muscle growth and growth hormone axis stimulation. This combination is frequently discussed in SARM communities as a way to maximize lean mass gains without injectables. It is also occasionally run alongside Cardarine, though Cardarine's abandoned dev...
LGD-4033 produces the most pronounced testosterone suppression of the commonly used SARMs. Phase I data documented dose-dependent suppression of testosterone, LH, and FSH at every dose tested. Recovery without intervention takes weeks to months and some users report prolonged suppression that requir...